News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 16, 2024

Type 2 Inflammation: The Link Between AD and PN

A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 inflammation-driven dermatologic conditions.

Episodes in this series

This series features 1 KOL.

EP. 1 Navigating the Challenges of Respiratory Diseases

1 KOL is featured in this series.

EP. 2 The Impact of Atopic Dermatitis and Prurigo Nodularis

This series features 1 KOL.

EP. 3 Linking Type 2 Inflammation to Asthma and COPD

This series features 1 KOL.

EP. 4 Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

1 KOL is featured in this series.

EP. 5 Type 2 Inflammation: The Link Between AD and PN

1 KOL is featured in this series.

EP. 6 Personalizing Treatment Selection

1 KOL is featured in this series.

EP. 7 Navigating Treatment Challenges in Chronic Skin Conditions

1 KOL is featured in this series.

EP. 8 Role of Biologics in Dermatological Care

This series features 1 KOL.

EP. 9 Biomarkers as Tools in Management of Type 2 Inflammation

This series features 1 KOL.

EP. 10 Strategies to Manage Type 2 Inflammation in Respiratory Diseases

1 KOL is featured in this series.

EP. 11 Addressing Unmet Needs and Emerging Agents

This series features 1 KOL.

EP. 12 Future Directions for Type 2 Inflammation Management

1 KOL is featured in this series.

EP. 13 Type 2 Inflammatory Diseases and Impact on Quality of Life

1 KOL is featured in this series.

EP. 14 Type 2 Inflammation Biomarkers

1 KOL is featured in this series.

EP. 15 How Type 2 Inflammation Influences Treatment Choices

1 KOL is featured in this series.

EP. 16 Complications of Uncontrolled Disease and Management of Comorbidities

1 KOL is featured in this series.

EP. 17 Patient Education and Emerging Therapies

1 KOL is featured in this series.

EP. 18 Unmet Needs and Future Research

What role does type 2 inflammation play in the connection between AD and PN?
What specific biomarkers can be used to identify patients with dermatologic conditions driven by type 2 inflammation, and how reliable are these biomarkers?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Peptide vial | Image credit: Iurii - stock.adobe.com

FDA Panel Backs 6 Peptides for Compounding

ByPearl Steinzor

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps